CN110179686A - 防护与皮肤接触的化学侵蚀剂作用的霜的用途 - Google Patents
防护与皮肤接触的化学侵蚀剂作用的霜的用途 Download PDFInfo
- Publication number
- CN110179686A CN110179686A CN201910485746.9A CN201910485746A CN110179686A CN 110179686 A CN110179686 A CN 110179686A CN 201910485746 A CN201910485746 A CN 201910485746A CN 110179686 A CN110179686 A CN 110179686A
- Authority
- CN
- China
- Prior art keywords
- lotion
- purposes
- agent
- chemical erosion
- sexes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000126 substance Substances 0.000 title claims abstract description 37
- 230000003628 erosive effect Effects 0.000 title claims abstract description 19
- 239000006210 lotion Substances 0.000 claims abstract description 80
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 26
- 239000002738 chelating agent Substances 0.000 claims abstract description 16
- 229910052782 aluminium Inorganic materials 0.000 claims abstract description 9
- 238000001467 acupuncture Methods 0.000 claims abstract description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960001484 edetic acid Drugs 0.000 claims abstract description 6
- 150000002148 esters Chemical class 0.000 claims abstract description 6
- 239000004411 aluminium Substances 0.000 claims abstract description 5
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims abstract description 5
- 150000002500 ions Chemical class 0.000 claims abstract description 3
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims description 21
- 206010012442 Dermatitis contact Diseases 0.000 claims description 11
- 239000007764 o/w emulsion Substances 0.000 claims description 11
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 9
- 208000010247 contact dermatitis Diseases 0.000 claims description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 230000033228 biological regulation Effects 0.000 claims description 6
- 239000004094 surface-active agent Substances 0.000 claims description 6
- YXIWHUQXZSMYRE-UHFFFAOYSA-N 1,3-benzothiazole-2-thiol Chemical compound C1=CC=C2SC(S)=NC2=C1 YXIWHUQXZSMYRE-UHFFFAOYSA-N 0.000 claims description 4
- 229930185605 Bisphenol Natural products 0.000 claims description 4
- 239000004471 Glycine Substances 0.000 claims description 4
- 101800002189 Hevein Proteins 0.000 claims description 4
- 229910052785 arsenic Inorganic materials 0.000 claims description 4
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 claims description 4
- 229910052793 cadmium Inorganic materials 0.000 claims description 4
- 229910052804 chromium Inorganic materials 0.000 claims description 4
- 229910001385 heavy metal Inorganic materials 0.000 claims description 4
- WKMZPSWMEXVKKG-XITFREQTSA-N hevein Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CS)C(=O)NCC(=O)OC(=O)CC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)[C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O)CC1=CNC2=CC=CC=C12 WKMZPSWMEXVKKG-XITFREQTSA-N 0.000 claims description 4
- 229910052745 lead Inorganic materials 0.000 claims description 4
- 229910052712 strontium Inorganic materials 0.000 claims description 4
- 229910052714 tellurium Inorganic materials 0.000 claims description 4
- KUAZQDVKQLNFPE-UHFFFAOYSA-N thiram Chemical compound CN(C)C(=S)SSC(=S)N(C)C KUAZQDVKQLNFPE-UHFFFAOYSA-N 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 3
- 239000003822 epoxy resin Substances 0.000 claims description 3
- 229920000647 polyepoxide Polymers 0.000 claims description 3
- 229960002447 thiram Drugs 0.000 claims description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 2
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- 229940024606 amino acid Drugs 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 229960003067 cystine Drugs 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- 230000002209 hydrophobic effect Effects 0.000 claims description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 2
- 230000006641 stabilisation Effects 0.000 claims description 2
- 238000011105 stabilization Methods 0.000 claims description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 150000001336 alkenes Chemical class 0.000 claims 1
- 125000004494 ethyl ester group Chemical group 0.000 claims 1
- 239000004744 fabric Substances 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 42
- 230000000694 effects Effects 0.000 description 21
- -1 that is Substances 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 238000012360 testing method Methods 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 210000002615 epidermis Anatomy 0.000 description 11
- 230000004888 barrier function Effects 0.000 description 9
- 210000001821 langerhans cell Anatomy 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 6
- 201000004624 Dermatitis Diseases 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 102000015696 Interleukins Human genes 0.000 description 4
- 108010063738 Interleukins Proteins 0.000 description 4
- 150000001335 aliphatic alkanes Chemical class 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 150000001924 cycloalkanes Chemical class 0.000 description 4
- 238000012744 immunostaining Methods 0.000 description 4
- 229940047122 interleukins Drugs 0.000 description 4
- 230000029052 metamorphosis Effects 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000002356 single layer Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 102000004890 Interleukin-8 Human genes 0.000 description 3
- 108090001007 Interleukin-8 Proteins 0.000 description 3
- 239000004909 Moisturizer Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- 239000005708 Sodium hypochlorite Substances 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 208000002029 allergic contact dermatitis Diseases 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 230000001166 anti-perspirative effect Effects 0.000 description 3
- 239000003213 antiperspirant Substances 0.000 description 3
- 239000002561 chemical irritant Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000003974 emollient agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 230000001333 moisturizer Effects 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 101710123661 Venom allergen 5 Proteins 0.000 description 2
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 2
- 241001135917 Vitellaria paradoxa Species 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000002009 allergenic effect Effects 0.000 description 2
- 229910000329 aluminium sulfate Inorganic materials 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000013043 chemical agent Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000007797 corrosion Effects 0.000 description 2
- 238000005260 corrosion Methods 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 238000007046 ethoxylation reaction Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036732 histological change Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 108010053156 lipid transfer protein Proteins 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000011241 protective layer Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229940057910 shea butter Drugs 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000007762 w/o emulsion Substances 0.000 description 2
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- 239000001500 (2R)-6-methyl-2-[(1R)-4-methyl-1-cyclohex-3-enyl]hept-5-en-2-ol Substances 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- NKJOXAZJBOMXID-UHFFFAOYSA-N 1,1'-Oxybisoctane Chemical compound CCCCCCCCOCCCCCCCC NKJOXAZJBOMXID-UHFFFAOYSA-N 0.000 description 1
- FEBUJFMRSBAMES-UHFFFAOYSA-N 2-[(2-{[3,5-dihydroxy-2-(hydroxymethyl)-6-phosphanyloxan-4-yl]oxy}-3,5-dihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-4-yl)oxy]-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl phosphinite Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(OC2C(C(OP)C(O)C(CO)O2)O)C(O)C(OC2C(C(CO)OC(P)C2O)O)O1 FEBUJFMRSBAMES-UHFFFAOYSA-N 0.000 description 1
- RDBCQSHUCYOVHR-UHFFFAOYSA-N 2-bromo-1-nitropropane-1,1-diol Chemical compound CC(Br)C(O)(O)[N+]([O-])=O RDBCQSHUCYOVHR-UHFFFAOYSA-N 0.000 description 1
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N 5-oxoproline Chemical compound OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 229920003319 Araldite® Polymers 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000005881 Calendula officinalis Nutrition 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 108010022172 Chitinases Proteins 0.000 description 1
- 102000012286 Chitinases Human genes 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 244000042664 Matricaria chamomilla Species 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 208000028571 Occupational disease Diseases 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 101000813258 Paspalum notatum Expansin-B Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 108010059820 Polygalacturonase Proteins 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 229920000289 Polyquaternium Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229920002305 Schizophyllan Polymers 0.000 description 1
- 102000008847 Serpin Human genes 0.000 description 1
- 108050000761 Serpin Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 244000044822 Simmondsia californica Species 0.000 description 1
- 235000004433 Simmondsia californica Nutrition 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 240000000785 Tagetes erecta Species 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 102000005937 Tropomyosin Human genes 0.000 description 1
- 108010030743 Tropomyosin Proteins 0.000 description 1
- 206010046742 Urticaria contact Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 101710196023 Vicilin Proteins 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- ZGUQGPFMMTZGBQ-UHFFFAOYSA-N [Al].[Al].[Zr] Chemical compound [Al].[Al].[Zr] ZGUQGPFMMTZGBQ-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- HZVVJJIYJKGMFL-UHFFFAOYSA-N almasilate Chemical compound O.[Mg+2].[Al+3].[Al+3].O[Si](O)=O.O[Si](O)=O HZVVJJIYJKGMFL-UHFFFAOYSA-N 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- REDXJYDRNCIFBQ-UHFFFAOYSA-N aluminium(3+) Chemical compound [Al+3] REDXJYDRNCIFBQ-UHFFFAOYSA-N 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 229940073669 ceteareth 20 Drugs 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000006757 chemical reactions by type Methods 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- SOROIESOUPGGFO-UHFFFAOYSA-N diazolidinylurea Chemical compound OCNC(=O)N(CO)C1N(CO)C(=O)N(CO)C1=O SOROIESOUPGGFO-UHFFFAOYSA-N 0.000 description 1
- 229960001083 diazolidinylurea Drugs 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229950006159 etersalate Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 235000002864 food coloring agent Nutrition 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- 229940098330 gamma linoleic acid Drugs 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000024278 histolysis Effects 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 208000001875 irritant dermatitis Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- MGIYRDNGCNKGJU-UHFFFAOYSA-N isothiazolinone Chemical compound O=C1C=CSN1 MGIYRDNGCNKGJU-UHFFFAOYSA-N 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- FBUKVWPVBMHYJY-UHFFFAOYSA-N noncarboxylic acid Natural products CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N palmityl palmitate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920002851 polycationic polymer Polymers 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 239000001944 prunus armeniaca kernel oil Substances 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000020195 rice milk Nutrition 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 150000000000 tetracarboxylic acids Chemical class 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/51—Chelating agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Detergent Compositions (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Preventing Corrosion Or Incrustation Of Metals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明涉及一种乳液用于皮肤针对化学侵蚀剂的防护的用途，所述乳液包含至少一种两性螯合剂，该两性螯合剂包含一种基于铝和乙二胺四乙酸或其三钠盐的通式为[Al(Y)Bn]c’Dc的复合物，其中B代表OH‑、BO2 ‑、H+，Y代表可以质子化四次以形成乙二胺四乙酸的四羧酸酯，n代表等于0、1、2或3的整数，D是抗衡离子，优选Na+，c是等于0、1、2或3的整数，c’是与c具有相同绝对值的相对数。
Description
本申请是申请号为201380037758.6、申请日为2013年7月17日、发明名称为防护与皮肤接触的化学侵蚀剂作用的霜的用途的申请的分案申请。
技术领域
本发明涉及用于防护可能与皮肤接触的化学侵蚀剂的产品领域。
发明内容
在操作化学侵蚀剂时，尤其是在工厂、实验室、美发沙龙等，常常发生这些产品意外飞溅而接触到皮肤的情形。10％-15％的职业病是皮肤病，其中后者的95％是接触皮炎。职业性接触皮炎主要影响手。每年在1000工作者中观察到0.7-1.5例。
皮肤刺激的频率与个体易感性和暴露在化学侵蚀剂的频率和持续时间呈函数关系。重要的因素例如是在潮湿的环境中工作，使用清洁剂、酸、碱、氧化剂、溶剂等。并且，应该强调的是，慢性刺激性接触皮炎也构成二次敏化的重要危险因素。
为了降低患上职业性皮肤病的风险，强烈建议戴手套。然而，戴上建议的手套工作时间里并不总是100％有效。实际上，常常发生戴手套并不完全符合的情形，尤其是在操作中度侵蚀剂时，因为使用者发现它过于约束。因此，操作侵蚀性化学剂的人倾向于限制戴手套的时长。并且，如果手套的材料不是完全适合于对其需要防护的化工产品和/或如果戴的时间延长超过渗透时间，则防护的效力可能只有一部分。再者，可能因为手套撕裂或因为侵蚀性化学剂可能通过手套的袖口或戴手套前后接触皮肤发生化学侵蚀剂的渗透。能对某些轻度侵蚀性的特殊物质或某些特殊过敏原形成物理屏障的霜的应用使保护皮肤免受这些试剂伤害变为可能，尤其是当这些试剂在戴手套前后接触皮肤时。
在过去的三十年间，这些防护霜的制备已经从经验阶段过渡到了科学研究阶段。皮肤防护制剂(霜和凝胶)是基于各种外用载体(一般是水包油或油包水乳液以及基于纤维素醚和丙烯酸聚合物的凝胶)。然而，这种制剂总是设计用于特定的环境条件，即，防护特定类型的刺激物。
因此，这种霜/凝胶现在有销售。出现的问题是这些制剂只能使皮肤防护窄范围的轻微侵蚀性的水溶性或油溶性试剂。这是由于这些制剂是基于力学效应而起作用的：一旦试剂渗透，霜就在皮肤和外部侵蚀剂之间形成屏障。这个屏障对不溶于其中的侵蚀剂是有效的。因此，这种产品的效力是降低的，因为它只考虑了溶解度，而没有考虑其他因素如分子量、分配系数、化学反应性等。这种产品未曾被广泛使用。
目前还没有能够使皮肤有效防护广泛的各种化学品尤其是过敏原的霜。
令人惊讶且预料不到的是，本发明人已经调配了一种用于皮肤针对所有类型化学侵蚀剂防护的霜。
发明概述
本发明总体上涉及一种霜或乳液用于皮肤针对化学侵蚀剂防护的用途，所述霜包含一种两性螯合剂。本发明还涉及所述乳液。在本发明中，乳液是指选自水包油乳液、油包水乳液、复合型乳液、微乳液、纳米乳液和它们的混合物的乳液。
更具体地，根据第一个方面，本发明涉及一种乳液用于皮肤针对化学侵蚀剂的防护，尤其是过敏原的用途。
根据第二个方面，本发明涉及所述乳液用于预防接触性皮炎的用途。
根据第三个方面，本发明涉及所述乳液。
根据第四个方面，本发明涉及制备所述乳液的方法。
以下更详细地描述本发明某些优选的实施方案。
发明详述
本发明涉及一种乳液用于皮肤针对化学侵蚀剂防护的用途，所述乳液包含至少一种两性螯合剂，该两性螯合剂包含一个基于铝和去质子化的乙二胺四乙酸的复合物，通式为[Al(Y)Bn]c’Dc，其中B代表OH-、BO2 -、H+，Y代表可以质子化四次以形成乙二胺四乙酸的四羧酸酯，n代表等于0、1、2或3的整数，D是抗衡离子，优选Na+，c是等于0、1、2或3的整数以及c’是与c具有相同绝对值的相对数。
所述两性螯合剂优选通过铝离子Al3+、配体Y和选自OH-、BO2 -或H+的稳定剂的准化学计量组合而形成。因此，其pH保持中性，其最低酸性pK在6-10范围内，其最高碱性pK在5-8范围内，且其最高碱性pK低于最低酸pK。
在本发明中，霜是指乳液，即，水包油乳液、油包水乳液、复合型乳液、微乳液、或纳米乳液。因此这两个术语“霜”和“乳液”在本发明中可以交换使用。
根据一个具体的实施方案，所述基于铝和Y的复合物用弱碱例如选自甘氨酸、组氨酸、精氨酸、赖氨酸、苯丙氨酸、丙氨酸、异亮氨酸、亮氨酸、蛋氨酸、脯氨酸，缬氨酸、色氨酸、丝氨酸、谷氨酰胺、胱氨酸和它们的混合物的氨基酸稳定。甘氨酸尤其适合。
所述乳液中存在的两性螯合剂基于乳液的总重量的含量是0.01-5wt％，优选0.1-2wt％，甚至更优选0.2-1wt％。低于0.01％的量不会获得充分的防护效果。高于5％，没有观察到明显的改进。
根据本发明，乳液用于外用，更具体地涂覆皮肤。
不希望受限于理论，本发明人的观点是，根据本发明的乳液可以形成针对化学侵蚀剂的物理化学屏障。更具体地，在施用并干燥后，无水的屏障层覆盖皮肤，从而在皮肤和外部环境间提供物理屏障，至于两性螯合剂，它通过与接触该霜层的化学制品的螯合或化学反应提供化学屏障。
通过该双重作用，阻止了侵蚀剂与皮肤的接触。
为了使其有效，乳液必须完全覆盖需要保护的皮肤区域，通常是手。必须定期将其施用于整个区域，比率约为0.5-5mg/cm2、优选约1-3mg/cm2、更优选约2mg/cm2。
为了最佳效果，最好是在接触化学侵蚀剂前的至少5分钟、优选至少10分钟、甚至更优选至少15分钟涂覆该产品。
根据活动，在皮肤表面形成的保护层会持续不同的时间长度。在任何情况下，每次洗手后都必须重新施用根据本发明的霜。不洗手和没有明显和/或重复的机械摩擦的情况下，保护层将长达4小时有效。如果活动造成了很多摩擦，则建议更为频繁地重新施用。因此，建议至少每4小时或每次洗手后重新施用根据本发明所述的乳液。
在本发明中，化学侵蚀剂包括化学刺激物和过敏性产品。化学刺激物包括属于CLP规定中定义的H311、H312、H314、H315、H317类物质及其混合物(关于物质及其混合物分类、标记和包装的规定(EC)第1272/2008号)。它们还包括pH为2-11.5的产品。
因此，在EC规定第1272/2008号中，产品H311被定义为与皮肤接触有毒的。产品H312被定义为与皮肤接触有害的。产品H314被定义为造成皮肤严重烧伤和眼部病变。产品H315被定义为造成皮肤刺激。产品H317被定义为可能造成皮肤过敏。
根据本发明所述的乳液符合标准NFS75601。该标准是关于作为皮肤表面的预防措施而施用以提供对中度侵蚀性产品的暂时防护的防护霜。“中度侵蚀性产品”是指在有关有害物质标记的规定中没有被分类为非常有毒、有毒、腐蚀或过敏的物质或制剂。该标准规定了这些防护霜的特点及其使用的限定。不适用于对可能的物理或微生物风险的防护。
该乳液可有效用于防护水溶性或不溶于水的化学刺激物。
作为水溶性刺激物的例子，我们可提及酸、碱、氯化产品等。更具体地，这些产品可以选自pH≤11.50的氢氧化钠、pH≥2.00的盐酸、高达12％的次氯酸钠、浓度可以达到5％的月桂基硫酸钠水溶液及其混合物。作为不溶于水的刺激物的例子，我们可提及长链烃溶剂、氯化溶剂及其混合物。特别地，这类产品可以选自矿物油、石油溶剂(C9-C16烷烃/环烷烃)及其混合物。我们也可提及常用产品如洗涤剂、胶水、剥离剂、木材处理产品、农业处理产品如杀虫剂、农药、化肥、水泥和砂浆、充填或加固岩腔的产品、染料。根据本发明的霜对于需要特殊标记毒性的产品的防护有效。
过敏产品包含与皮肤接触能够在以前致敏的个体中引起过敏反应的有机物、粒子或物体(原子、分子、蛋白质、糖蛋白或任意其他具有复杂结构的大分子有机物)。这种过敏反应可能导致皮肤损伤甚至是病理学现象。作为过敏产品的例子，我们可提及选自重金属(例如Al、As、Cd、Cr、Hg、Ni、Pb、Sr、Te)、二硫化四甲基秋兰姆、2-巯基苯并噻唑、氨基甲酸苄酯、双酚、丙烯酸乙酯、啊拉尔代特(Araldite)506环氧树脂、橡胶蛋白、甲醛、蛋白类过敏原(例如抑制蛋白、原肌球蛋白、LTP(脂质转移蛋白)、Bet v1样蛋白PR-10、polcalcin、β小白蛋白、2s白蛋白、β苹果菌素、聚半乳糖醛酸酶、Ag5(抗原5)、白蛋白、酪蛋白、脂钙蛋白、第5组草、11s球蛋白、7s豌豆球蛋白样球蛋白、第4组草、木瓜蛋白酶样半胱氨酸蛋白酶、磷脂酶A1、丝氨酸蛋白酶抑制剂、透明质酸酶、1类几丁质酶、类甜蛋白(thaumatin-likeproteins)等)及其混合物的过敏原。
使用根据本发明的乳液的效力通过形态分析测试。
为了证明对刺激物的效力，采用了两种方法：形态分析和允许白细胞介素尤其是IL-6和IL-8分析的研究。
通过马森氏三色法(Goldner变种)染色分析细胞形态。形态变化的存在表明测试物已经造成严重刺激，其因此改变了细胞结构。施用根据本发明的水包油乳液后，使乳液覆盖的皮肤区域接触以下化学侵蚀剂后没有观察到形态变化：pH 11.50的氢氧化钠、pH 2.00的盐酸、12％的次氯酸钠、5％的月桂基硫酸钠、矿物油和石油溶剂(C9-C16烷烃/环烷烃)。
效力也在通过白细胞介素分析的实验中被证实。真皮中白细胞介素IL-6(首先产生的)和IL-8(随后产生的)的浓度是皮肤发炎过程的函数。在皮肤上施用乳液后，使乳液覆盖的皮肤区域接触以下化学侵蚀剂后没有观察到白细胞介素6或8含量的明显增加：pH11.50的氢氧化钠、pH 2.00的盐酸、12％的次氯酸钠、5％的月桂基硫酸钠、矿物油和石油溶剂(C9-C16烷烃/环烷烃)。
使用根据本发明的两性螯合剂的效力通过基于以下理论的形态分析进行测试：朗氏(Langerhan)细胞是存在于表皮且含有伯贝克颗粒的树突状细胞。它们通常存在于表皮棘层的淋巴结和皮肤中。这些捕获抗原的特化细胞在皮肤接触过敏原时被激活。这是敏化过程开始的第一个迹象。免疫标记方法，尤其是针对朗氏细胞的CD1a表面受体的免疫标记方法，使测量它们的数量以及观察它们从表皮到真皮的迁移成为可能。如果抗原被阻止，即没有被表皮朗氏细胞捕获，本发明的预防组合物是有效的。因此后者不会迁移到真皮。根据本发明的组合物的效力因此通过每厘米表皮没有迁移的朗氏细胞数测定。使乳液覆盖的皮肤区域接触重金属(例如Al、As、Cd、Cr、Hg、Ni、Pb、Sr、Te)、二硫化四甲基秋兰姆、2-巯基苯并噻唑、氨基甲酸苄酯、双酚、丙烯酸乙酯、啊拉尔代特506环氧树脂、橡胶蛋白和甲醛后没有观察到这些细胞数的明显迁移。
根据另一个方面，本发明涉及用于预防接触皮炎的乳液。
接触皮炎是由长期或反复暴露在过敏原或刺激物质下引起的皮肤反应。刺激性接触皮炎(ICD)和过敏性接触皮炎(ACD)之间有区别。
在过敏性接触皮炎中，立即反应型(接触性荨麻疹)和延迟反应型(湿疹)有区别。
此外，刺激性皮炎可能是急性或慢性特征。
本发明中的“接触皮炎”是指所有类型的皮肤反应。
根据本发明的乳液防止皮肤与所述试剂的直接接触，因此有助于通过构建形成无水膜的物理屏障以及化学屏障(利用两性螯合剂的性质以及根据本发明的霜的反应性能)避免接触皮炎。
因此，所述乳液防止了由某些化学品或甚至是由戴保护性手套引起的接触皮炎。
根据本发明的乳液可以每天施用。使用的条件与上述的相同。
以下所述的实施方案与此类乳液及该乳液的用途有关。
根据一个具体的实施方案，所述乳液是水包油乳液。
乳液包含一个水相、一个油相和至少一种表面活性剂。
表面活性剂可以是HLB为3-10的疏水性的(对于不是水包油的乳液)或HLB为11-18的亲水性的。该表面活性剂选自乙氧基化的脂肪醇、脂肪酸和酯(例如鲸蜡硬脂醇聚醚-12、鲸蜡硬脂醇聚醚-20、鲸蜡硬脂醇聚醚-33、20-乙氧基化的硬脂基鲸蜡醇、聚甘油2-聚羟基硬脂酸酯、油酸甘油酯、山梨糖醇酯、甘油酯、PEG-单/二月桂酸酯、PEG-单/二硬脂酸酯、异壬酸鲸蜡硬脂醇酯、硬脂酸甘油酯等)、羧酸盐、乙氧基羧酸盐(例如硬脂酸钠/钾、烷基羧酸、烷基聚乙二醇醚羧酸、聚乙二醇烷基酚醚羧酸、羧甲基化醇、乙氧基羧酸盐、醚羧酸盐等)及其混合物。
表面活性剂的基于乳液总重量的含量为0.1-10％，优选0.5-5％，甚至更优选1-3％重量。
油相包含合成的或天然的蜡或油，其选自棕榈提取物、蜂蜡、乳木果油(sheabutter)、甘油三酯、硬脂、脂肪酸酯(例如鲸蜡硬脂醇、棕榈酸鲸蜡酯的二辛基醚、碳酸二辛酯、鲸蜡硬脂基异壬酸酯、二硬脂酰-三碳酸酯二聚体等)、硅酮油、硬脂酸锌、聚异丁烯、辛基十二烷醇、辛基癸酰木糖苷、脂肪醇、脂肪酸(例如月桂酸、肉豆蔻酸、硬脂酸等)、植物油(例如葵花油、荷荷巴油、椰子油、大豆油、杏仁油等)及其混合物。
基于乳液的总重量，油相占至多98wt％，尤其至多70wt％，优选5-50％，甚至更优选10-20％。
水相主要包含水，优选纯净水。基于乳液总重量，它占1-90wt％，优选30-80wt％，甚至更优选50-70wt％。
根据本发明的乳液可以包含赋予皮肤有益性质的多种试剂。这些试剂根据它们的溶解度或者存在于水相或者存在于油相中。
这些试剂尤其是保湿剂、润肤剂、止汗剂等。
保湿剂和润肤剂可以选自尿囊素、多元醇(例如甘油、甘油聚合物、丙二醇、山梨醇等)、植物提取物(例如芦荟、洋甘菊、黄瓜、金盏草等的提取物)、玻尿酸、吡咯烷酮羧酸、尿素、壳聚糖、生育酚、泛醇、丁二醇、磷脂、亚油酸、γ-亚油酸、α-红没药醇及其混合物。
基于乳液的总重量，保湿剂和润肤剂的浓度为0.1-20wt％，优选0.5-10wt％，甚至更优选1-5wt％。
止汗剂可以选自铝盐，优选倍半盐酸铝盐、铝和锆的盐、铝-锆八氯水合(octachlorohydrex)甘氨酸复合物及其混合物。基于乳液的总重量，止汗剂的浓度为0.1-50wt％，优选10-30wt％，甚至更优选15wt％。
乳液还可以包含改善纹理的添加剂，例如调节剂和增稠剂。
调节剂可以选自根据INCI命名法表示的聚阳离子聚合物，例如聚季铵盐、季铵化胶、季铵化磷脂及其混合物。基于乳液的总重量，调节剂的浓度为0.1-20wt％，优选0.5-10wt％，甚至更优选0.5-5wt％。
增稠剂可以选自丙烯酸的聚合物和共聚物、C10-30烷基丙烯酸酯/丙烯酸酯交联聚合物、聚丙烯酰胺、泊洛沙姆、纤维素衍生物(酯和醚)、二氧化硅、气相二氧化硅、硅酸盐、例如镁-铝硅酸盐、甲壳素及其衍生物、明胶、黄原胶、葡聚糖、结冷胶、角叉菜胶、藻酸盐、琼脂-琼脂、琼脂、果胶、金合欢树胶、刺梧桐胶、黄蓍胶、阿拉伯胶、瓜尔豆胶、角豆树胶、淀粉及其衍生物、硬葡聚糖和它们的混合物。基于乳液的总重量，增稠剂的浓度为0.1-10wt％，优选0.1-5wt％，甚至更优选0.5-3wt％。
乳液还可以包含防腐剂。后者可以选自：对羟基苯甲酸酯、异噻唑啉酮、咪唑烷基脲、二唑烷基脲、溴代硝基丙二醇、苯氧乙醇、山梨酸及其盐、苯甲酸及其盐、苯氧乙醇、苯甲醇和它们的混合物。浓度是化妆品中允许的浓度。
最后，制剂可以包含化妆品和食品着色剂、香料、香味、pH调节剂(例如柠檬酸、乳酸、磷酸、氢氧化钠、氢氧化钾、氨甲基丙醇，三乙醇胺等)和它们的混合物。基于乳液的总重量，其浓度为0.1-50wt％，优选10-30wt％，甚至更优选15wt％。
根据另一个方面，本发明涉及制备所述乳液的方法。
所述乳液可以通过本领域技术人员已知的任何技术制备。然而，为了使其稳定性最佳，最好是首先制备水相，通过冷混合将两性螯合剂加入水相中，然后将该制剂加入油相中混合乳化。
在第二个实施方案中，最好是首先制备水相，通过热混合将两性螯合剂加入水相中，然后该制剂加入油相中混合乳化。
热混合可以在50-90℃，优选60-80℃，甚至更优选70℃下进行。
在本发明中，如果乳液在室温储存6个月，优选1年后没有观察到相分离，则认为其稳定性是满意的。
将基于以下实施例更详细地说明本发明。
实施例
以下实施例描述了本发明的某些实施方案。然而，应该理解这些实施例仅为说明的目的，而不以任何方式限制本发明的范围。
在这些实施例中，所用的两性螯合剂具有以下结构：[AlYBO2]2-Na+ 2。
实施例1：外用乳液
制备包含以下产品的乳液：
该水包油乳液具有以下特征：
–温度20(+/-1)℃，转子转速3/20rpm下测得的Brookfield粘度为18000cP，
–pH 6.45，
–室温储存6个月后没有发生相分离。
实施例2：外用乳液
按照实施例1中相同的方法，制备包含以下的乳液：
该水包油乳液具有以下特征：
–温度20(+/-1)℃，转子转速3/20rpm下测得的Brookfield粘度为21000cP，
–pH 6.55，
–室温储存6个月后没有发生相分离。
实施例3：外用乳液
按照实施例1中相同的方法，制备包含以下的乳液：
该水包油乳液具有以下特征：
–温度20(+/-1)℃，转子转速3/20rpm下测得的Brookfield粘度为14500cP，
–pH 6.80，
–室温储存6个月后没有发生相分离。
实施例4：外用乳液
按照实施例1中相同的方法，制备包含以下的乳液：
该水包油乳液具有以下特征：
–温度20(+/-1)℃，转子转速3/20rpm下测得的Brookfield粘度为12000cP，
–pH 4.30，
–室温储存6个月后没有发生相分离。
实施例5：针对刺激物的效力测试
准备来自于一位49岁白种女性腹部整形的平均直径为10mm的皮肤外植体。在富含5％CO2的潮湿环境下于37℃的BEM(BIO-EC外植体培养基)培养基中保持这些外植体的存活。
测试该霜针对以下刺激物的效力：
水溶液中的刺激物：
·pH 11.5的氢氧化钠-参考：S/4945/PB15Fisher Chemical；
·pH 2.00的盐酸-参考：H/1000/PB18Fisher Chemical；
·12％的次氯酸钠-参考：27895Prolabo；
·5％w/w的月桂醇硫酸钠-Cognis
油溶性刺激物：
·矿物油-液体石蜡Codex Interchimie；
·石油溶剂(C9-C16烷烃/环烷烃)-Shellsol D60，Shell。
在T0，在皮肤外植体上涂覆来自实施例1的霜，剂量为3mg/cm2。晾干15分钟。在被保护的皮肤外植体(测试)和未被保护的皮肤外植体(对照)上涂25μl的选自上述列表的刺激物溶液。静置至T4h(代表暴露在刺激物下4小时)。
平行地，以相同方法准备用所述霜保护但不与测试物质接触的外植体(对照)。
通过马森氏三色法(Goldner变种)染色后分析细胞形态来测试针对刺激物的防护效力。存在形态变化表明测试物已经造成严重刺激，因此其改变了细胞结构。
在T0和T4h对所有外植体取样并拍照。
pH 11.5(+/-0.1)氢氧化钠溶液的结果如图1和2所示。图1表示在T0的外植体，图2表示在T4h的外植体。
在T0，角质层是好的，在表面有中度的收紧和中度的角化，深处严重一点。
表皮有4-5层细胞形态良好，基底层有轻微海绵状结构。真皮和表皮之间联接处轮廓清晰。乳头状真皮有相当厚的胶原纤维的稠密网络。它包含很多细胞，且不包含明显的组织溶解区。
在T4h，未被保护的外植体的表皮有4-5层细胞具有确定的形态变化。这些变化的特征是相当大的细胞质变性、核固缩和在生发层中明确的海绵状结构。
然而，被保护的外植体(“测试”)和“对照”没有明显的组织学变化。
在其他测试的刺激物中观察到完全相似的结果。
没有细胞变化或低水平的细胞变化以及白细胞介素的低浓度证实了，实施例1中的水包油乳液有效地保护了皮肤免受测试刺激物的伤害。
实施例6：针对过敏原的效力测试
如以上实施例5所述制备外植体。
测试所述霜针对以下过敏原的效力：
·重金属(Al、As、Cd、Cr、Hg、Ni、Pb、Sr、Te)-ECP多元素标准V参考0C467028Merck；
·二硫化四甲基秋兰姆-T2 420；
·2-巯基苯并噻唑-M3301；
·氨基甲酸苄酯-B18200；
·双酚-13302；
·丙烯酸乙酯-W241806；
·啊拉尔代特506环氧树脂-A3183；
·橡胶蛋白-乳胶4335932；
·30％w/w甲醛-116 99031。
在T0，在皮肤外植体上涂覆来自实施例2的霜，剂量为3mg/cm2。晾干15分钟。在被保护的皮肤外植体(测试)和未被保护的皮肤外植体(空白)上涂25μl选自上述列表的一种过敏原溶液。静置至T4h(代表暴露在过敏原下4小时，没有冲洗或粗鲁的摩擦)。
平行地，以相同方法准备被所述霜保护但不与测试物质接触的外植体(对照)。
通过朗氏细胞的CD1a受体的免疫染色分析来测试针对过敏原的防护效力。首先，用抗CD1a单克隆抗体(参考IM1590，克隆O10，Beckman Coulter)在室温下免疫染色石蜡包被的朗氏细胞切片1小时。用链霉亲和素/生物素系统(Vector，PK-7200)加强该免疫染色并用VIP(Vector，SK-4600)显色。用马森氏苏木精明矾复染细胞核。对每个切片中表皮上的朗氏细胞计数。用Olympus Cell软件测量每个切片的长度，并计算每厘米表皮中的朗氏细胞平均数。
通过CD1a免疫染色分析来测试针对免疫原的防护效力。首先，用抗CD1a单克隆抗体(参考IM1590，克隆O10，Beckman Coulter)在室温下免疫染色石蜡包被的朗氏细胞切片1小时。用链霉亲和素/生物素系统(Vector，PK-7200)加强该免疫染色并用VIP(Vector，SK-4600)显色。用马森氏苏木精明矾复染细胞核。对每个切片中表皮上的朗氏细胞计数。用Olympus Cell软件测量每个切片的长度，并计算每厘米表皮中的朗氏细胞平均数。
通过没有迁移的朗氏细胞数来测试针对免疫原的防护效力。
在T0和T4h对所有外植体取样并显微拍照。
结果如图3和4所示。图3表示T0时针对橡胶蛋白的外植体，图4表示T4h时针对橡胶蛋白的外植体。
在T0，角质层是好的，在表面有收紧和中度的角蛋白填充，往下一点更为明显。表皮具有4-5层细胞其中形态良好，以及生发层中有轻微海绵状结构。真皮和表皮之间联接处轮廓明显。乳头状真皮具有相当厚的形成稠密网络的纤维。它包含很多细胞，且不包含明显的组织溶解区。
未被保护的外植体的表皮具有4-5层细胞其中具有明显的形态变化。这些变化的特征是相当大的细胞质变性(蛋白质降解)、明显的固缩和在生发层中明显的海绵状结构。
然而，被保护的和对照外植体没有明显的组织学变化。
在其他测试的过敏原中观察到完全相似的结果。
没有细胞变化或低水平变化以及白细胞介素的低浓度证实了，来自实施例2的水包油乳液有效地保护了皮肤免受测试过敏原的伤害。
Claims (14)
1.一种乳液用于皮肤针对化学侵蚀剂防护的用途，所述乳液包含至少一种两性螯合剂，所述两性螯合剂包含一种基于铝和乙二胺四乙酸或其三钠盐的通式为[Al(Y)Bn]c’Dc的复合物，其中B代表OH-、BO2 -、H+，Y代表可以质子化四次以形成乙二胺四乙酸的四羧酸酯，n代表等于0、1、2或3的整数，D是抗衡离子，优选Na+，c是等于0、1、2或3的整数，以及c’是与c具有相同绝对值的相对数。
2.根据权利要求1所述的乳液的用途，其特征是，所述化学侵蚀剂选自CLP规定中的H311、H312、H314、H315、H317类物质(规定(EC)第1272/2008号)、pH为2-11.5的产品和它们的混合物。
3.根据权利要求1或2所述的乳液的用途，用于皮肤针对过敏原的防护。
4.根据权利要求3所述的乳液的用途，其特征是，所述过敏原选自重金属(例如Al、As、Cd、Cr、Hg、Ni、Pb、Sr、Te)、二硫化四甲基秋兰姆、2-巯基苯并噻唑、氨基甲酸苄酯、双酚、丙烯酸乙酯、阿拉尔代特506环氧树脂、橡胶蛋白、甲醛和它们的混合物。
5.根据权利要求1所述的乳液的用途，用于预防接触性皮炎。
6.根据权利要求1-5任一项所述的乳液的用途，其特征是，所述乳液以约0.5-5mg/cm2、优选约1-3mg/cm2、更优选约2mg/cm2的比率均匀施用到整个区域上。
7.根据权利要求1-6任一项所述的乳液的用途，其特征是，在接触化学侵蚀剂前的至少5分钟、优选至少10分钟、甚至更优选至少15分钟施用所述乳液。
8.根据权利要求1-7任一项所述的乳液的用途，其特征是，最多每4小时，优选每次洗手后，重新施用所述乳液。
9.根据权利要求1-8任一项所述的乳液的用途，其特征是，基于所述乳液的总重量，所述两性螯合剂的浓度是0.01-5wt％。
10.根据权利要求1-9任一项所述的乳液的用途，其特征是，所述两性螯合剂通过选自甘氨酸、组氨酸、精氨酸、赖氨酸、苯丙氨酸、丙氨酸、异亮氨酸、亮氨酸、蛋氨酸、脯氨酸，缬氨酸、色氨酸、丝氨酸、谷氨酰胺、胱氨酸和它们的混合物的氨基酸稳定。
11.根据权利要求1-10任一项所述的乳液的用途，其特征是，所述乳液包含至少一种表面活性剂，所述表面活性剂可以是HLB为3-10的疏水性的或HLB为11-18的亲水性的。
12.根据权利要求1-11任一项所述的乳液的用途，其特征是，基于所述乳液的总重量，所述表面活性剂的浓度是0.1-10wt％，优选0.5-5wt％，甚至更优选1-3wt％。
13.根据权利要求1-12任一项所述的乳液的用途，其特征是，所述乳液是水包油乳液。
14.根据权利要求1-13任一项所定义的乳液用于皮肤针对化学侵蚀剂的防护。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1256939 | 2012-07-18 | ||
| FR1256939A FR2993466B1 (fr) | 2012-07-18 | 2012-07-18 | Utilisation d'une creme de protection contre les effets des agents chimiques agressifs en contact avec la peau |
| CN201380037758.6A CN104507501A (zh) | 2012-07-18 | 2013-07-17 | 防护与皮肤接触的化学侵蚀剂作用的霜的用途 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380037758.6A Division CN104507501A (zh) | 2012-07-18 | 2013-07-17 | 防护与皮肤接触的化学侵蚀剂作用的霜的用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110179686A true CN110179686A (zh) | 2019-08-30 |
Family
ID=47137836
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380037758.6A Pending CN104507501A (zh) | 2012-07-18 | 2013-07-17 | 防护与皮肤接触的化学侵蚀剂作用的霜的用途 |
| CN201380037698.8A Pending CN104470501A (zh) | 2012-07-18 | 2013-07-17 | 两性螯合剂用于预防接触性过敏的用途 |
| CN201910485746.9A Pending CN110179686A (zh) | 2012-07-18 | 2013-07-17 | 防护与皮肤接触的化学侵蚀剂作用的霜的用途 |
| CN201810186400.4A Pending CN108606964A (zh) | 2012-07-18 | 2013-07-17 | 两性螯合剂用于预防接触性过敏的用途 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380037758.6A Pending CN104507501A (zh) | 2012-07-18 | 2013-07-17 | 防护与皮肤接触的化学侵蚀剂作用的霜的用途 |
| CN201380037698.8A Pending CN104470501A (zh) | 2012-07-18 | 2013-07-17 | 两性螯合剂用于预防接触性过敏的用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810186400.4A Pending CN108606964A (zh) | 2012-07-18 | 2013-07-17 | 两性螯合剂用于预防接触性过敏的用途 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10953024B2 (zh) |
| EP (2) | EP2874604B1 (zh) |
| CN (4) | CN104507501A (zh) |
| AU (2) | AU2013291792B2 (zh) |
| BR (2) | BR112015001018B1 (zh) |
| CA (2) | CA2878650C (zh) |
| DK (2) | DK2874661T3 (zh) |
| ES (2) | ES2690060T3 (zh) |
| FR (1) | FR2993466B1 (zh) |
| IN (1) | IN2014DN10924A (zh) |
| MX (2) | MX356811B (zh) |
| NO (1) | NO2874604T3 (zh) |
| NZ (2) | NZ703258A (zh) |
| PL (2) | PL2874661T3 (zh) |
| PT (1) | PT2874604T (zh) |
| SI (1) | SI2874661T1 (zh) |
| TR (1) | TR201815143T4 (zh) |
| WO (2) | WO2014013194A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3093001B1 (fr) * | 2019-02-22 | 2022-06-10 | Prevor Int | Composition pour enlever des residus chimiques et ses utilisations |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2604900A1 (fr) * | 1986-10-08 | 1988-04-15 | Blomet Marie Claude | Solution physiologique pour le lavage des parties du corps humain ayant ete mises en contact avec un acide fluorhydrique et concentre pour sa preparation |
| US5763486A (en) * | 1993-04-19 | 1998-06-09 | Marie-Claude Blomet epouse Meyer | Process for preparing a composition for the treatment of thermal or chemical burns |
| WO2001093858A2 (fr) * | 2000-06-07 | 2001-12-13 | Meyer Marie Claude | Utilisation d'un complexe d'aluminium et de ligand ethylenediamine-tetraacetique pour la prevention et/ou le traitement des urticaires |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5091171B2 (en) * | 1986-12-23 | 1997-07-15 | Tristrata Inc | Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use |
| US5665804A (en) * | 1996-02-05 | 1997-09-09 | Dow Corning Corporation | Silicone latex solvent thickening |
| SE9604610D0 (sv) * | 1996-12-16 | 1996-12-16 | Noviscens Ab | Medical composition |
| US6242042B1 (en) * | 1998-09-14 | 2001-06-05 | Lrc Products Ltd. | Aqueous coating composition and method |
| US6582683B2 (en) * | 2000-01-04 | 2003-06-24 | Skinvisible Pharmaceuticals, Inc. | Dermal barrier composition |
| GB0403702D0 (en) * | 2004-02-19 | 2004-03-24 | Boots Co Plc | Skincare compositions |
| WO2005040114A1 (en) * | 2003-10-14 | 2005-05-06 | Oxagen Limited | Compounds having crth2 antagonist activity |
| GB0324084D0 (en) * | 2003-10-14 | 2003-11-19 | Oxagen Ltd | Compounds |
| US20090019224A1 (en) * | 2005-02-02 | 2009-01-15 | Pocrass Alan L | Data Storage and Transfer Device and Method |
| ES2720332T3 (es) * | 2008-01-18 | 2019-07-19 | Vystar Corp | Látex de caucho natural con alergenicidad reducida y método de fabricación |
| WO2011041680A2 (en) * | 2009-10-02 | 2011-04-07 | The Brigham And Women's Hospital, Inc. | Compositions and methods of prophylaxis for contact dermatitis |
-
2012
- 2012-07-18 FR FR1256939A patent/FR2993466B1/fr active Active
-
2013
- 2013-07-17 NO NO13747452A patent/NO2874604T3/no unknown
- 2013-07-17 AU AU2013291792A patent/AU2013291792B2/en active Active
- 2013-07-17 MX MX2015000786A patent/MX356811B/es active IP Right Grant
- 2013-07-17 DK DK13747451.6T patent/DK2874661T3/en active
- 2013-07-17 PL PL13747451T patent/PL2874661T3/pl unknown
- 2013-07-17 CA CA2878650A patent/CA2878650C/fr active Active
- 2013-07-17 CA CA2878882A patent/CA2878882C/fr active Active
- 2013-07-17 CN CN201380037758.6A patent/CN104507501A/zh active Pending
- 2013-07-17 PT PT137474524T patent/PT2874604T/pt unknown
- 2013-07-17 PL PL13747452T patent/PL2874604T3/pl unknown
- 2013-07-17 BR BR112015001018-0A patent/BR112015001018B1/pt active IP Right Grant
- 2013-07-17 AU AU2013291793A patent/AU2013291793B2/en active Active
- 2013-07-17 BR BR112015001019-9A patent/BR112015001019B1/pt active IP Right Grant
- 2013-07-17 ES ES13747451.6T patent/ES2690060T3/es active Active
- 2013-07-17 DK DK13747452.4T patent/DK2874604T3/en active
- 2013-07-17 CN CN201380037698.8A patent/CN104470501A/zh active Pending
- 2013-07-17 NZ NZ703258A patent/NZ703258A/en unknown
- 2013-07-17 TR TR2018/15143T patent/TR201815143T4/tr unknown
- 2013-07-17 ES ES13747452.4T patent/ES2667709T3/es active Active
- 2013-07-17 EP EP13747452.4A patent/EP2874604B1/fr active Active
- 2013-07-17 WO PCT/FR2013/051717 patent/WO2014013194A1/fr active Application Filing
- 2013-07-17 SI SI201331206T patent/SI2874661T1/sl unknown
- 2013-07-17 CN CN201910485746.9A patent/CN110179686A/zh active Pending
- 2013-07-17 EP EP13747451.6A patent/EP2874661B1/fr active Active
- 2013-07-17 WO PCT/FR2013/051718 patent/WO2014013195A1/fr active Application Filing
- 2013-07-17 CN CN201810186400.4A patent/CN108606964A/zh active Pending
- 2013-07-17 IN IN10924DEN2014 patent/IN2014DN10924A/en unknown
- 2013-07-17 US US14/415,428 patent/US10953024B2/en active Active
- 2013-07-17 NZ NZ703409A patent/NZ703409A/en unknown
- 2013-07-17 MX MX2015000785A patent/MX359747B/es active IP Right Grant
- 2013-07-17 US US14/415,146 patent/US11197874B2/en active Active
-
2021
- 2021-02-10 US US17/172,434 patent/US20210275553A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2604900A1 (fr) * | 1986-10-08 | 1988-04-15 | Blomet Marie Claude | Solution physiologique pour le lavage des parties du corps humain ayant ete mises en contact avec un acide fluorhydrique et concentre pour sa preparation |
| US5763486A (en) * | 1993-04-19 | 1998-06-09 | Marie-Claude Blomet epouse Meyer | Process for preparing a composition for the treatment of thermal or chemical burns |
| WO2001093858A2 (fr) * | 2000-06-07 | 2001-12-13 | Meyer Marie Claude | Utilisation d'un complexe d'aluminium et de ligand ethylenediamine-tetraacetique pour la prevention et/ou le traitement des urticaires |
Non-Patent Citations (1)
| Title |
|---|
| 张兆旺: "《中药药剂学》", 31 January 2003 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4299142B2 (ja) | 陽イオン界面活性剤と陰イオン界面活性剤を含む安定な組成物 | |
| CN109498494A (zh) | 一种清爽控油无硅油洗发露及其制备方法 | |
| ES2343528T3 (es) | Uso para el extracto de gymnema sylvestris. | |
| AU2017240068B2 (en) | Antimicrobial peptide stimulating cleansing composition | |
| BRPI1013598B1 (pt) | formulações para limpeza e cuidados de partes corporais humanas ou animais, que contêm ésteres de ácidos sorbitancarboxílico e uso de ésteres de ácido sorbitancarboxílico em formulações de limpeza ou cuidados | |
| CN103648468A (zh) | 微乳液在化妆清洁组合物中的用途 | |
| CN113599290B (zh) | 包含牛磺酸、精氨酸、甘氨酸的个人护理组合物 | |
| JP6089152B2 (ja) | 剥脱性の毛髪保持促進製剤 | |
| US20150320662A1 (en) | Non-Petrochemically Derived Cationic Emulsifiers and Related Compositions and Methods | |
| CN107427429A (zh) | 具有pH缓冲系统的乳化化妆材料组合物 | |
| AU2014330911A1 (en) | Composition | |
| CN109640938A (zh) | 提高皮肤微生物群的微生物多样性的方法 | |
| ES2369853T3 (es) | Partículas de piritiona metálicas recubiertas para el tratamiento de microorganismos. | |
| CN112656733A (zh) | 一种具有抑菌作用的清洁组合物及无防腐剂的清洁产品 | |
| JP2007077146A (ja) | 皮膚の炎症を抑制するか減少させるための組成物 | |
| WO2018049558A1 (en) | Methods of improving skin appearance | |
| CN106983698A (zh) | 一种抑制表皮油脂的组合物和由其组成的化妆品 | |
| Epstein | Cosmeceutical vehicles | |
| KR20200125628A (ko) | 스킨 케어 유익성을 제공하기 위한 조성물 및 사용 방법 | |
| EP1593371A1 (en) | Skin or hair care composition | |
| CN110179686A (zh) | 防护与皮肤接触的化学侵蚀剂作用的霜的用途 | |
| CN102802596B (zh) | 含有季戊四醇酯的护发剂和护发洗发化合物 | |
| JP4696107B2 (ja) | ブクホルジア属に属する植物の抽出物の化粧品および医薬品における使用 | |
| CN104382763B (zh) | 一种具有抗静电作用的身体乳液 | |
| AU2020405222A1 (en) | Personal care compositions and methods for the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |